IMMB News: Immunotech Relocates to New Research & Development Laboratory Facility 03/01/2013 09:15:00 AM IMMB News: Immunotech Laboratories Inc. Announces Clinical Trials Updates For Company's AIDS-HIV "IPF" Medicines 02/20/2013 01:32:00 PM IMMB News: Immunotech Laboratories, Inc. Announces Analyst Report Issued by Market Advisors, Inc. 02/19/2013 09:15:00 AM IMMB News: Immunotech Laboratories Receives $2M Funding Approval To Begin European Clinical Trials Testing For Company's Patented "IPF" ... 02/13/2013 09:20:00 AM IMMB News: Immunotech Laboratories Appoints New Chief Financial Advisor to Strengthen Company's Growth and International Expansion Plan 02/07/2013 09:22:00 AM
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind.
Immunotech's flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.